依加替莫德超越免疫球蛋白疗法治疗 CIDP

IF 28.2 1区医学 Q1 CLINICAL NEUROLOGY

Nature Reviews Neurology Pub Date : 2024-11-28 DOI:10.1038/s41582-024-01045-8

Jan D. Lünemann

{"title":"依加替莫德超越免疫球蛋白疗法治疗 CIDP","authors":"Jan D. Lünemann","doi":"10.1038/s41582-024-01045-8","DOIUrl":null,"url":null,"abstract":"The FDA recently approved efgartigimod for the treatment of chronic inflammatory demyelinating polyradiculopathy, providing an alternative to the immunoglobulin therapy that has been the standard treatment for years. The approval has the potential to improve access to treatment and outcomes, but many challenges remain in implementing trial findings into clinical practice.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"8 1","pages":""},"PeriodicalIF":28.2000,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Moving beyond immunoglobulin therapy for CIDP with efgartigimod\",\"authors\":\"Jan D. Lünemann\",\"doi\":\"10.1038/s41582-024-01045-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The FDA recently approved efgartigimod for the treatment of chronic inflammatory demyelinating polyradiculopathy, providing an alternative to the immunoglobulin therapy that has been the standard treatment for years. The approval has the potential to improve access to treatment and outcomes, but many challenges remain in implementing trial findings into clinical practice.\",\"PeriodicalId\":19085,\"journal\":{\"name\":\"Nature Reviews Neurology\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":28.2000,\"publicationDate\":\"2024-11-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41582-024-01045-8\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41582-024-01045-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

美国食品和药物管理局（FDA）最近批准依加替莫德用于治疗慢性炎症性脱髓鞘多发性神经病，为多年来一直作为标准疗法的免疫球蛋白疗法提供了一种替代方案。这项批准有望改善治疗的可及性和疗效，但将试验结果应用于临床实践仍面临许多挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Moving beyond immunoglobulin therapy for CIDP with efgartigimod

The FDA recently approved efgartigimod for the treatment of chronic inflammatory demyelinating polyradiculopathy, providing an alternative to the immunoglobulin therapy that has been the standard treatment for years. The approval has the potential to improve access to treatment and outcomes, but many challenges remain in implementing trial findings into clinical practice.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Neurology 医学-临床神经学

CiteScore

29.90

自引率

0.80%

发文量

138

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Neurology aims to be the premier source of reviews and commentaries for the scientific and clinical communities we serve. We want to provide an unparalleled service to authors, referees, and readers, and we work hard to maximize the usefulness and impact of each article. The journal publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians working in the field of neurology. Our broad scope ensures that the work we publish reaches the widest possible audience. Our articles are authoritative, accessible, and enhanced with clearly understandable figures, tables, and other display items. This page gives more detail about the aims and scope of the journal.